Neuphoria Therapeutics (NEUP) to Release Quarterly Earnings on Wednesday

Neuphoria Therapeutics (NASDAQ:NEUP) is expected to release its Q4 2026 results before the market opens on Wednesday, September 2nd. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Wednesday, September 30, 2026 at 4:00 PM ET.

Neuphoria Therapeutics Stock Performance

Shares of Neuphoria Therapeutics stock opened at $3.76 on Tuesday. The firm’s 50 day moving average is $3.80 and its 200 day moving average is $4.36. The firm has a market capitalization of $20.30 million, a PE ratio of -0.34 and a beta of 0.75. Neuphoria Therapeutics has a 1 year low of $3.19 and a 1 year high of $21.40.

Analysts Set New Price Targets

NEUP has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday. Finally, HC Wainwright cut Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Neuphoria Therapeutics currently has a consensus rating of “Hold” and an average target price of $21.00.

Institutional Investors Weigh In On Neuphoria Therapeutics

Several hedge funds have recently added to or reduced their stakes in NEUP. Geode Capital Management LLC lifted its holdings in shares of Neuphoria Therapeutics by 33.3% in the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock worth $67,000 after purchasing an additional 4,325 shares in the last quarter. Persistent Asset Partners Ltd lifted its position in shares of Neuphoria Therapeutics by 173.1% during the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after buying an additional 8,495 shares in the last quarter. Commonwealth Equity Services LLC bought a new position in shares of Neuphoria Therapeutics during the 4th quarter worth approximately $43,000. XTX Topco Ltd purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter worth approximately $47,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter worth approximately $54,000. 15.90% of the stock is currently owned by institutional investors and hedge funds.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.